XML 15 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Mar. 31, 2016
Jun. 30, 2015
Current assets:    
Cash and cash equivalents $ 34,813 $ 35,364
Accounts receivable, net 765,506 596,155
Prepaid expenses and other current assets 72,756 34,591
Total current assets 873,075 666,110
Goodwill 2,609,903 2,189,816
Intangible assets, net 286,476 195,182
Property and equipment, net 81,799 63,689
Supplemental retirement savings plan assets 88,885 89,012
Accounts receivable, long-term 7,889 8,188
Other long-term assets 31,391 30,033
Total assets 3,979,418 3,242,030 [1]
Current liabilities:    
Current portion of long-term debt 53,965 38,965
Accounts payable 112,065 56,840
Accrued compensation and benefits 214,000 185,830
Other accrued expenses and current liabilities 163,359 118,046
Total current liabilities 543,389 399,681
Long-term debt, net of current portion 1,431,437 1,024,599
Supplemental retirement savings plan obligations, net of current portion 77,323 76,860
Deferred income taxes 269,062 200,237
Other long-term liabilities 86,161 60,381
Total liabilities $ 2,407,372 $ 1,761,758
COMMITMENTS AND CONTINGENCIES
Shareholders' equity:    
Preferred stock $0.10 par value, 10,000 shares authorized, no shares issued
Common stock $0.10 par value, 80,000 shares authorized; 41,743 shares issued and 24,308 outstanding at March 31, 2016 and 41,622 shares issued and 24,184 outstanding at June 30, 2015 $ 4,174 $ 4,162
Additional paid-in capital 555,367 547,979
Retained earnings 1,617,317 1,519,149
Accumulated other comprehensive loss (28,760) (14,960)
Treasury stock, at cost (17,435 and 17,438 shares, respectively) (576,187) (576,193)
Total CACI shareholders' equity 1,571,911 1,480,137
Noncontrolling interest 135 135
Total shareholders' equity 1,572,046 1,480,272
Total liabilities and shareholders' equity $ 3,979,418 $ 3,242,030
[1] Balances have been adjusted for the reclassification of debt issuance costs and deferred taxes related to the adoption of ASU 2015-03 and ASU 2015-17. See Note 2 for additional information.